This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Achillon, Cyclacel: Early Volume Plays

Stocks in this article: CYCC ACHN SCLN TUES

NEW YORK ( TheStreet) -- Several stocks trading under $5 were poised to move on above-average volume during Monday's session.

Cyclacel Pharmaceuticals (CYCC - Get Report) jumped by 18 cents, or 6%, to $3.18. Cycacel began its surge last week after a lung-cancer drug had successful laboratory tests reported in two industry journals. The 50-day average daily volume for Cyclacel is 3.5 million, according to the Nasdaq.

Achillion Pharmaceuticals (ACHN) was among the most active pre-market trades, jumping by 46 cents, or 13.5%, to $3.85 in the premarket session on Monday, after the company reported additional positive results for a hepatitis C drug. The 50-day average daily volume for Achillon is 444,000, according to the Nasdaq.

SciClone Pharmaceuticals (SCLN - Get Report) spiked 32 cents, or close to 13%, to $2.85 in the premarket session after the biotech firm lifted its sale guidance for 2010 -- a 15% increase. The 50-day average daily volume for SciClone is 320,000, according to the Nasdaq.

Tuesday Morning (TUES - Get Report) rose by 71 cents, or 23%, to $3.74 in the premarket session, after the closeout retailer announced higher quarterly earnings and a positive outlook for the next quarter. The 50-day average daily volume for Tuesday Morning is 199,000, according to the Nasdaq.

-- Written by Eric Rosenbaum in New York.

Check out all of Monday's high-volume, under-$5 stocks at the Dollar Store

Copyright 2009 TheStreet.com Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs